Neurology Specialists, Inc.

Dayton, Ohio 45417

0 studies enrolling now · 17 studies all time

What they study most

Alzheimer's Disease, Autoimmune Diseases of the Nervous System, Brain Atrophy, Clinically Isolated Syndrome, Disease Progression, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Parkinson Disease, Parkinson's Disease, Partial Epilepsy, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

Studies at this site

• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures — Completed
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis — Completed
• A Cooperative Clinical Study of Abatacept in Multiple Sclerosis — Completed
• Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis — Stopped early
• Autologous T Cell Vaccine (TCV) for Multiple Sclerosis — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy — Completed
• A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) — Completed
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis — Completed
• Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations — Completed